A5085415407- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- COVID-19 and healthcare impacts
- Respiratory Support and Mechanisms
- Pneumocystis jirovecii pneumonia detection and treatment
- Neuroblastoma Research and Treatments
- Intensive Care Unit Cognitive Disorders
- Pneumonia and Respiratory Infections
- Respiratory viral infections research
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- SARS-CoV-2 and COVID-19 Research
- Pancreatic and Hepatic Oncology Research
- Antifungal resistance and susceptibility
- Glioma Diagnosis and Treatment
- Antibiotic Use and Resistance
- Surgical site infection prevention
- Antibiotics Pharmacokinetics and Efficacy
- Chronic Myeloid Leukemia Treatments
- Oral and gingival health research
- Neutropenia and Cancer Infections
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Whipple's Disease and Interleukins
Vall d'Hebron Hospital Universitari
2021-2024
Vall d'Hebron Institute of Oncology
2024
Universitat Autònoma de Barcelona
2020-2022
ABSTRACT Background Modulation of the immune system to prevent lung injury is being widely used against new coronavirus disease (COVID-19) despite scarcity evidence. Methods We report preliminary results from Vall d’Hebron prospective cohort study at University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and were treated tocilizumab until March 25 th . The primary endpoint...
We aim to assess risk factors related early readmission in previous hospitalized patients with COVID-19.
Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate (ADC), was the first ADC approved for patients with metastatic triple-negative breast cancer (mTNBC) who had received at least two prior lines of therapy advanced disease. Although SG has shown promising clinical activity in treating brain metastases both ASCENT randomized trials and real-world analysis, its utility leptomeningeal carcinomatosis (LC) remains underexplored. We report diagnostic therapeutic process patient...
Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best predict mortality in hospitalized receiving active systemic treatment. Our main goal was to develop a predictive model 90-day upon admission.
Introduction: Hospital-acquired pneumonia (HAP) and ventilator-associated (VAP) are prevalent nosocomial infections with a worrisomely increasing prevalence of multidrug-resistant causative organisms, including those resistance to carbapenems. The addition relebactam, β-lactamase inhibitor, imipenem treatment restores the antimicrobial activity against most Gram-negative bacteria, some carrying β‐lactamase enzyme-type carbapenemases.Areas covered: aim this article is summarize current...
Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about SARS-CoV-2 vaccines and recent chemotherapy morbidity mortality this specific population. Methods: We described among STS across ‘Omicron’ (15 December 2021–31 January 2022), ‘Pre-vaccination’ (27 February 2020–30 November 2020), ‘Alpha-Delta’ phase (01 2020–14 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR ) severity were...
Whipple’s disease (WD) is a rare infectious with wide clinical spectrum. Associated thrombotic manifestations are not well described in WD, only related to ‘stroke-like syndrome’. We present case of 39-year-old man 1-year history self-limited episodes fever, associated generalised adenopathies and recurrent superficial deep venous thrombosis events, which have resorted four times despite the anticoagulant treatment. Finally, patient diagnosed WD. Following treatment improved his general...
e24155 Background: Venous Thromboembolisms (VTE) is a common complication in cancer patients (p) and one of the lead causes cancer-related death. Digestive neoplasms have specific characteristics VTE incidence treatment. There lack data regarding impact p with neuroendocrine tumors (NET). Currently few studies addressed NET, an estimated 7.5%. Nevertheless, there no evidence from large datasets to address implications thrombosis NET p. In present study, we review treatment unicentric cohort....